Safety Profile of Drugs for Advanced Melanoma: A Report Based on 2008 to 2018 United States Food and Drug Administration Data

This review describes the safety profiles of all drug classes used for the treatment of advanced melanoma. Adverse reactions diversified over time; notably, skin and retinal disorders were frequently associated with targeted therapies and endocrine disorders with immunotherapies.

British Journal of Clinical Pharmacology